Switch theme
Sign up to access all valuation multiples
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
2016
5.8K+
LTM Revenue $2.7B
LTM EBITDA -$3.8B
$5.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Moderna has a last 12-month revenue (LTM) of $2.7B and a last 12-month EBITDA of -$3.8B.
In the most recent fiscal year, Moderna achieved revenue of $3.2B and an EBITDA of -$3.4B.
Moderna expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Moderna valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.7B | XXX | $3.2B | XXX | XXX | XXX |
| Gross Profit | $1.4B | XXX | $1.7B | XXX | XXX | XXX |
| Gross Margin | 52% | XXX | 54% | XXX | XXX | XXX |
| EBITDA | -$3.8B | XXX | -$3.4B | XXX | XXX | XXX |
| EBITDA Margin | -138% | XXX | -106% | XXX | XXX | XXX |
| EBIT | -$4.0B | XXX | -$3.9B | XXX | XXX | XXX |
| EBIT Margin | -146% | XXX | -123% | XXX | XXX | XXX |
| Net Profit | -$3.7B | XXX | -$3.6B | XXX | XXX | XXX |
| Net Margin | -135% | XXX | -111% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Moderna's stock price is $27.
Moderna has current market cap of $10.3B, and EV of $5.0B.
See Moderna trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.0B | $10.3B | XXX | XXX | XXX | XXX | $-9.60 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Moderna has market cap of $10.3B and EV of $5.0B.
Moderna's trades at 1.6x EV/Revenue multiple, and -1.5x EV/EBITDA.
Equity research analysts estimate Moderna's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Moderna has a P/E ratio of -2.8x.
See valuation multiples for Moderna and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10.3B | XXX | $10.3B | XXX | XXX | XXX |
| EV (current) | $5.0B | XXX | $5.0B | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | -1.3x | XXX | -1.5x | XXX | XXX | XXX |
| EV/EBIT | -1.3x | XXX | -1.3x | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.8x | XXX | -2.9x | XXX | XXX | XXX |
| EV/FCF | -1.4x | XXX | -1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialModerna's last 12 month revenue growth is -20%
Moderna's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $1.0M for the same period.
Moderna's rule of 40 is -69% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Moderna's rule of X is -189% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Moderna and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -20% | XXX | -14% | XXX | XXX | XXX |
| EBITDA Margin | -138% | XXX | -106% | XXX | XXX | XXX |
| EBITDA Growth | -7% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -69% | XXX | -126% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -189% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 142% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 178% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Moderna acquired XXX companies to date.
Last acquisition by Moderna was XXXXXXXX, XXXXX XXXXX XXXXXX . Moderna acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Moderna founded? | Moderna was founded in 2016. |
| Where is Moderna headquartered? | Moderna is headquartered in United States of America. |
| How many employees does Moderna have? | As of today, Moderna has 5.8K+ employees. |
| Who is the CEO of Moderna? | Moderna's CEO is Mr. Stephane Bancel. |
| Is Moderna publicy listed? | Yes, Moderna is a public company listed on NAS. |
| What is the stock symbol of Moderna? | Moderna trades under MRNA ticker. |
| When did Moderna go public? | Moderna went public in 2018. |
| Who are competitors of Moderna? | Similar companies to Moderna include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Moderna? | Moderna's current market cap is $10.3B |
| What is the current revenue of Moderna? | Moderna's last 12 months revenue is $2.7B. |
| What is the current revenue growth of Moderna? | Moderna revenue growth (NTM/LTM) is -20%. |
| What is the current EV/Revenue multiple of Moderna? | Current revenue multiple of Moderna is 1.8x. |
| Is Moderna profitable? | Yes, Moderna is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Moderna? | Moderna's last 12 months EBITDA is -$3.8B. |
| What is Moderna's EBITDA margin? | Moderna's last 12 months EBITDA margin is -138%. |
| What is the current EV/EBITDA multiple of Moderna? | Current EBITDA multiple of Moderna is -1.3x. |
| What is the current FCF of Moderna? | Moderna's last 12 months FCF is -$3.5B. |
| What is Moderna's FCF margin? | Moderna's last 12 months FCF margin is -129%. |
| What is the current EV/FCF multiple of Moderna? | Current FCF multiple of Moderna is -1.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
